PeptiDream Inc. PPTDF
Set alert
6.80 USD 0.00 0.00%
At close · Oct 30
6.80 Day range 6.80
5.88 52-week range 12.85
- YTD
- -45.51%
- 1 year
- -38.74%
- Open
- 6.80
- Prev close
- 6.80
- Mkt cap
- 874.26M
- Vol
- 250
- Avg vol
- 460
- EPS
- -0.18
- P/E
- 0.00
More statistics
- Low
- 6.80
- High
- 6.80
6M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 5, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| RSI: Overbought | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| RSI: Oversold | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| RSI: Oversold | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 5 months ago |
News
- PeptiDream (PPTDF) Expected to Announce Quarterly Earnings on Wednesday
- PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
- PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
- Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
- PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
- PeptiDream Inc. (PPTDF) Q4 2025 Earnings Call Transcript
- Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
- PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
Your note
Sign in to keep a note on PPTDF — it syncs with the Stock Master app.